Voorheesville, NY, United States of America

Robert Jason Herr

This inventor holds 19 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Neuropharmaceuticals. Top assignees: Emisphere Technologies, Inc., Eolas Therapeutics, Inc., Agenebio, Inc.. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Jason Herr. Retrieved from https://idiyas.com/inventor/robert-jason-herr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 5)

% Patents Active = 68.4

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 39(Granted Patents)

Company Filing History:

5 out of 183

Emisphere Technologies, Inc.

patents

3 out of 7

Eolas Therapeutics, Inc.

Albany Molecular Research, Inc.

patents

5. 2 out of 4,514

Eli Lilly and Company

patents

6. 2 out of 2,405

Merck Sharp + Dohme Corp.

patents

7. 2 out of 99

Sage Therapeutics, Inc.

patents

8. 2 out of 3,073

The General Hospital Corporation

patents

9. 2 out of 16,025

University of California

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Neuroactive Steroids

Benzodiazepine Derivatives

Gamma-Secretase Modulators

Orexin Receptor Antagonists

Fatty Acid Binding Protein Inhibitors

Glucagon-Like Peptide

Melanocortin-4 Receptor Agonists

Pyridazinone Derivatives

PPAR Modulators

Cognitive Impairment Treatments

Dyslipidemia

Oral Delivery Formulations

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12291535 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2025-05-06),

2. 12071453 - Neuroactive steroids, compositions, and uses thereof (2024-08-27),

3. 11498940 - Neuroactive steroids, compositions, and uses thereof (2022-11-15),

4. 11414425 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2022-08-16),

5. 11117884 - Potent gamma-secretase modulators (2021-09-14),

6. 10597401 - Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof (2020-03-24),

7. 10472346 - Potent gamma-secretase modulators (2019-11-12),

8. 9896452 - Substituted prolines/piperidines as orexin receptor antagonists (2018-02-20),

9. 9499517 - Substituted prolines / piperidines as orexin receptor antagonists (2016-11-22),

10. 9440982 - Substituted prolines/piperidines as orexin receptor antagonists (2016-09-13),

11. 8889683 - Substituted quinoxalines as inhibitors of fatty acid binding protein (2014-11-18),

12. 8765796 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide (2014-07-01),

13. 8552039 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide (2013-10-08),

14. 8546581 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide (2013-10-01),

15. 8232274 - Pyridazinone derivatives useful as glucan synthase inhibitors (2012-07-31),

Title: Innovations by Robert Jason Herr in Cognitive Treatment

Introduction

Robert Jason Herr, based in Voorheesville, NY, is a prolific inventor with a remarkable portfolio of 19 patents. His work primarily focuses on advancements in pharmaceuticals aimed at addressing cognitive impairments associated with various CNS disorders. His innovative contributions have the potential to significantly enhance treatment options for patients worldwide.

Latest Patents

Among his most recent patents is one related to benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. This invention involves the use of benzodiazepine derivatives in the formulation of therapies aimed at mitigating cognitive decline, particularly in conditions such as Alzheimer's disease, PTSD, schizophrenia, and several other neurological disorders. Herr’s approach emphasizes utilizing α5-containing GABAreceptor agonists, which could play a vital role in alleviating age-related cognitive impairment and even certain types of brain cancers.

Another notable patent describes neuroactive steroids designed to act as GABA modulators. This invention provides novel pharmaceutical compositions that can induce sedation or anesthesia, showcasing Herr’s commitment to advancing therapeutic methodologies in neurology.

Career Highlights

Robert has made significant strides in his career, contributing to various esteemed organizations, including Emisphere Technologies, Inc. and Eolas Therapeutics, Inc. His experience in these companies has enabled him to collaborate on innovative treatments that cater to pressing medical needs, further underscoring his role as a key figure in pharmaceutical advancements.

Collaborations

Throughout his career, Herr has worked alongside talented colleagues such as Qin Jiang and Louis Nickolaus Jungheim. These collaborations have likely enhanced the breadth and depth of his research, fostering an environment conducive to groundbreaking discoveries in the field of cognitive enhancement therapies.

Conclusion

Robert Jason Herr's unwavering dedication to developing innovative solutions for cognitive impairment reaffirms his status as an influential inventor. With his extensive patent portfolio, he continues to pave the way for new and effective treatments that have the potential to change the lives of many individuals facing cognitive challenges.

Profile summary based on public USPTO records.